IFITM proteins assist cellular uptake of diverse linked chemotypes

Kevin Lou(Howard Hughes Medical Institute), Douglas R. Wassarman(Howard Hughes Medical Institute), Tangpo Yang(University of California, San Francisco), YiTing Paung(Stony Brook University), Ziyang Zhang(Howard Hughes Medical Institute), Thomas O’loughlin(University of California, San Francisco), Megan K. Moore(Howard Hughes Medical Institute), Regina K. Egan(Massachusetts General Hospital), Patricia Greninger(Massachusetts General Hospital), Cyril H. Benes(Harvard University), Markus A. Seeliger(Stony Brook University), Jack Taunton(University of California, San Francisco), Luke A. Gilbert(University of California, San Francisco), Kevan M. Shokat(Howard Hughes Medical Institute)
Science
December 8, 2022
Cited by 37Open Access
Full Text

Abstract

The search for cell-permeable drugs has conventionally focused on low-molecular weight (MW), nonpolar, rigid chemical structures. However, emerging therapeutic strategies break traditional drug design rules by employing flexibly linked chemical entities composed of more than one ligand. Using complementary genome-scale chemical-genetic approaches we identified an endogenous chemical uptake pathway involving interferon-induced transmembrane proteins (IFITMs) that modulates the cell permeability of a prototypical biopic inhibitor of MTOR (RapaLink-1, MW: 1784 g/mol). We devised additional linked inhibitors targeting BCR-ABL1 (DasatiLink-1, MW: 1518 g/mol) and EIF4A1 (BisRoc-1, MW: 1466 g/mol), uptake of which was facilitated by IFITMs. We also found that IFITMs moderately assisted some proteolysis-targeting chimeras and examined the physicochemical requirements for involvement of this uptake pathway.


Related Papers

No related papers found

Powered by citation graph analysis